Table 2.
CAFF300 | TEA300 | COMBO | PLA | p | |
---|---|---|---|---|---|
Bench Press 1RM (kg) | 120.0 ± 16.0 | 119.0 ± 16.0 | 120.0 ± 16.0 | 117.0 ± 16.0 | < 0.05 |
Bench Press RTF (# reps) | 12.0 ± 3.0 | 12.0 ± 3.0 | 13.0 ± 3.0 | 12.0 ± 3.0 | 0.72 |
Squat 1RM (kg) | 151.0 ± 24.0 | 149.0 ± 25.0 | 150.0. ± 24.0 | 148.0 ± 21.0 | 0.18 |
Squat RTF (# reps) | 13.0 ± 3.0 | 11.0 ± 3.0 | 12.0. ± 4.0 | 11.0 ± 4.0 | 0.16 |
2 k Row TT (s) | 478.0 ± 35.1 | 479.0 ± 39.6 | 478.6 ± 42.5 | 483.2 ± 45.6 | 0.87 |
Significance (p < 0.05) was found in bench press 1RM, but further post-hoc analyses revealed no significant group effects (p ≥ 0.05). Data presented as mean ± SD
CAFF300 300 mg of caffeine, TEA300 300 mg of TeaCrine®, COMBO 150 mg of caffeine and 150 mg of TeaCrine®, PLA placebo, 1 RM one-repetition maximum, Reps repetitions, kg kilograms, s seconds, RTF reps to failure, 2 k 2 km, TT time-trial